Miklos Fogarasi

Dr. Miklos Fogarasi

Frank H. Netter MD School of Medicine, North Haven, Connecticut, USA
orcid

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 September 2021 in Nutrients
Verified
Journal Article
Open access
PDF file
ALAlexa Beth Lisevick
Alexa Beth Lisevick
BCBrenda Cartmel
Brenda Cartmel
MHMaura Harrigan
Maura Harrigan
FLFangyong Li
Fangyong Li
TSTara Sanft
Tara Sanft
LFLeah Ferrucci
Leah Ferrucci
Lifestyle interventions among breast cancer survivors with obesity have demonstrated successful short-term weight loss, but data on long-term weight maintenance are limited. We evaluated long-term weight loss maintenance in 100 breast cancer survivors with overweight/obesity in the efficacious six-month Lifestyle, Exercise, and Nutrition (LEAN) Study (intervention = 67; usual care = 33). Measured baseline and six-month weights were available for 92 women. Long-term weight data were obtained from electronic health records. We assessed weight trajectories between study completion (2012–2013) and July 2019 using growth curve analyses. Over up to eight years (mean = 5.9, SD = 1.9) of post-intervention follow-up, both the intervention (n = 60) and usual care (n = 32) groups declined in body weight. Controlling for body weight at study completion, the yearly weight loss rate in the intervention and usual care groups was –0.20 kg (−0.2%/year) (95% CI: 0.06, 0.33, p = 0.004) and −0.32 kg (−0.4%/year) (95% CI: 0.12, 0.53, p = 0.002), respectively; mean weight change did not differ between groups (p = 0.31). It was encouraging that both groups maintained their original intervention period weight loss (6% intervention, 2% usual care) and had modest weight loss during long-term follow-up. Breast cancer survivors in the LEAN Study, regardless of randomization, avoided long-term weight gain following study completion.

2 September 2021 in Journal of Cancer Survivorship
Verified
Journal Article
Closed access
PDF file
ASAlexandra Smith
Alexandra Smith
MFMiklos Fogarasi
Miklos Fogarasi
MLMaryam B. Lustberg
Maryam B. Lustberg
LNLarissa Nekhlyudov
Larissa Nekhlyudov

28 August 2024 in Journal for ImmunoTherapy of Cancer
Verified
Journal Article
Open access
PDF file
AMAnna K Maloney
Anna K Maloney
AGAnita Giobbie-Hurder
Anita Giobbie-Hurder
NKNikita Katukota
Nikita Katukota
MFMiklos Fogarasi
Miklos Fogarasi
POPatrick A Ott
Patrick A Ott
EBElizabeth Buchbinder
Elizabeth Buchbinder
Background The combination of ipilimumab and nivolumab is a highly effective treatment for metastatic cutaneous melanoma. However, immune-related adverse events (irAEs) are common, often necessitating treatment interruption and the use of immunosuppressive agents. There is no data on the impact of resuming nivolumab on survival following recovery from the irAE and completion of immunosuppressive treatment. Patients and methods In this retrospective analysis, we examined a cohort of patients treated with ipilimumab/nivolumab who developed irAEs requiring treatment interruption and immunosuppressive therapy. The differences in physician practice patterns at our institution allowed us to examine the survival effect of restarting single-agent nivolumab. A multivariate analysis of clinical factors associated with improved survival was performed. Results We identified 165 patients who were treated with ipilimumab/nivolumab and developed irAEs requiring treatment interruption and immunosuppressive therapy. Patients with the best overall response of progressive disease were excluded. Of the remaining 122 patients, 46 resumed single-agent nivolumab. When stratified by age and adjusted for sex, M-stage, lactate dehydrogenase (LDH), therapy duration, and irAE type, the effect of resumption of nivolumab on survival was highly significant (p=0.02). Patients who resumed nivolumab had a 68% reduction in the hazard of death compared with patients who had not yet or never resumed nivolumab (HR: 0.32, 95% CI: 0.12 to 0.84). Of the patients who resumed nivolumab, 12 (26%) patients had subsequent irAEs, with five patients having grade 3 irAEs. No grade 4 or 5 irAEs were noted. Conclusions Resuming single-agent nivolumab following a treatment interruption for ipilimumab/nivolumab-associated irAE and completion of immunosuppressive therapy increased overall survival compared with discontinuing nivolumab permanently in patients with metastatic melanoma. Toxicity observed post-resumption of single-agent nivolumab was manageable with no severe irAEs observed.

1 October 2002
Verified
Journal Article
Closed access
SKShivaani Kummar
Shivaani Kummar
TCThomas E Ciesielski
Thomas E Ciesielski
MFMiklos Fogarasi
Miklos Fogarasi

1 August 2001 in Clinical Colorectal Cancer
Verified
Journal Article
Closed access
MFMiklos Fogarasi
Miklos Fogarasi
RZRichard S. Zelkowitz
Richard S. Zelkowitz
SMStephen A. Messana
Stephen A. Messana
JAJames A. Arrighi
James A. Arrighi
JSJohn P. Seibyl
John P. Seibyl
SKShivaani Kummar
Shivaani Kummar

22 March 2018 in Cureus
Verified
Journal Article
Open access
PDF file
NRNaveen Kumar Reddy
Naveen Kumar Reddy
FBFranklin C. Brown
Franklin C. Brown
MFMiklos Fogarasi
Miklos Fogarasi
JYJames B. Yu
James B. Yu
JHJudith Hess
Judith Hess
VCVeronica Chiang
Veronica Chiang
Longevity in cancer patients with brain metastases is increasingly being observed. This raises discussions about how best to maintain a good quality of life for these patients. Recent data suggest that post-treatment quality of life (QoL) can be maintained using new treatment options, but little data exist regarding the QoL in long-term survivors. This study of 19 patients surviving greater than two years from the initial treatment of brain metastases suggests that long-term QoL can be better than at the start of treatment and perhaps even better than normal, especially between three and five years post-treatment. This improved QoL seems mostly attributable to improved functional and social well-being and is possible as long as emotional and physical well-being are maintained within the normal range.